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Abstract Interaction of the Escherichia coli PapD chaperone 
with the synthetic peptide PapG308-314 (Thr-Met-Val-Leu-
Ser-Phe-Pro), corresponding to the seven C-terminal residues of 
the PapG pilus subunit, was studied by transferred nuclear 
Overhauser effect (TRNOE) spectroscopy. The observation of 
cross-peaks corresponding to either intraresidue or sequential 
CaH/NH and CPH/NH TRNOEs and the absence of sequential 
NH;/NHi+i TRNOEs indicate that the peptide binds to PapD in 
an extended conformation. In addition, line-broadening effects 
gave information of the peptide's mode of interaction with PapD. 
These observations were in excellent agreement with a recent 
crystal structure of a PapG peptide complexed with PapD. 
© 1997 Federation of European Biochemical Societies. 
Key words: P pili; PapD chaperone; Protein-peptide 
interaction; NMR; Transferred NOE 
1. Introduction 
Gram-negative bacteria have evolved filamentous polymeric 
protein structures called pili to mediate attachment to eukary-
otic cells as an early event in bacterial infections [1]. A well-
characterized example is uropathogenic Escherichia coli which 
express P pili that contain the adhesin PapG at the pilus tip. 
papG mediates binding to the disaccharide a-D-galactopyra-
nosyl-(1^4)-|3-D-galactopyranose [a-D-Gal-(1^4)-p-D-Gal] pres-
ent in the globoseries of glycolipids on epithelial cells lining 
the urinary tract [2,3]. P pili are heteropolymeric protein 
structures consisting of a large number of subunits of six 
different types which make up a thick pilus rod joined to a 
thinner adhesive tip fibrillum [4,5]. P pili are assembled by the 
periplasmic chaperone PapD which is not itself incorporated 
into the pilus. PapD binds to each of the pilus subunit types 
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as they are translocated across the cytoplasmic membrane and 
escorts them in assembly-competent, native-like conforma-
tions through the periplasm to outer membrane assembly sites 
[1]. X-ray crystallography revealed the PapD to consist of two 
immunoglobulin-like domains oriented in a boomerang shape 
such that a cleft is formed between the domains [6]. 
The PapD chaperone has been shown to bind to the con-
served C-terminal part of the different pilus subunits [7,8]. 
Recently, synthetic peptides which were derived from the pilus 
subunit C-termini and ranged in size from seven to 19-mers 
were shown to be bound by PapD and to inhibit complex 
formation between PapD and the adhesin papG [8,9]. The 
crystal structure of PapD complexed with the most potent 
peptide, which corresponds to the 19 C-terminal residues of 
PapG (PapG296-314), was also determined and refined to 3.0 
A resolution [8]. The peptide bound in an extended confor-
mation with its C-terminal residue (Pro314) anchored within 
the interdomain cleft of PapD and forming a parallel [5-strand 
interaction with strand Gl in the N-terminal domain of 
PapD. Within the crystal, the PapD-peptide p-sheet was ex-
tended even further as a result of non-crystallographic 2-fold 
symmetry that placed a second PapD-peptide complex adja-
cent to the first so that the two bound peptide chains inter-
acted as antiparallel P-strands. This dimerization was pro-
posed to be a consequence of crystal packing. 
It can not be ruled out that the structure of the complex 
between papD and PapG296-314 was influenced of by the 
dimerization in the crystal. Therefore, we have now investi-
gated the conformation of a peptide bound to PapD in sol-
ution, and the interactions in the complex, using TRNOE 
experiments [10-12]. The peptide PapG308-314 (Thr-Met-
Val-Leu-Ser-Phe-Pro) was chosen for these studies since it 
appears to represent the minimal peptide bound by PapD 
[8,9]. In addition, the aggregation state of PapD in solution 
was analyzed with asymmetrical flow field-flow fractionation 
in the presence and absence of peptide. 
2. Materials and methods 
PapG308-314 was synthesized by 9-fluorenylmethoxycarbonyl 
(Fmoc) solid-phase strategy and purified as described in [9]. The 
asymmetrical flow field-flow fractionation experiment was carried 
out using a 0.1 mg/ml solution of PapD in PBS (pH = 7.4) with and 
without the peptides PapG296-314 and PapG308-314 in a 1:1 molar 
ratio. An experimental set-up as previously described was used [13]. 
Three identical peptide solutions were prepared for NMR spectros-
copy by dissolving PapG308-314 in 50 mM phosphate buffer, pH 6.0, 
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containing 10% D 2 0 and 0.02% NaN3 to a concentration of 0.5 mM. 
The low concentration was used due to the low solubility of the 
peptide. A stock solution of PapD in PBS (2 mg/ml), produced and 
purified as described in [6], was concentrated to 0.2 mM by centrifu-
gation in an Ultrafree micro concentrator (cut-off = 5 kDa, Millipore, 
Bedford, MA) prior to dilution into one of the peptide solutions. The 
PapD concentration was 0.02 mM giving a peptide/protein ratio of 
25:1. A control sample was prepared by dissolving lyophilized Cal-
bindin D28k, produced and purified as described in [14], into another 
of the peptide solutions to give a peptide/protein ratio of 10:1. 
NMR spectra were obtained at 599.89 MHz on a Varian 600 Unity 
plus spectrometer. Phase sensitive NOESY [15,16], ROESY [17,18] 
and TOCSY [19] spectra were acquired at 27°C using the water res-
onance at 4.75 ppm as internal shift reference. Presaturation was used 
to attenuate the water signal except in the NOESY experiments where 
pulse field gradients were used to suppress the water signal. A 
WATERGATE-NOESY pulse sequence [20] was modified according 
to [21]. The NOESY spectra were acquired with mixing times of 20, 
200 and 500 ms and the ROESY spectra were acquired with a con-
tinuous wave spin-lock mixing time of 200 ms. The TOCSY experi-
ments were performed using the modification suggested by Ranee [22] 
and the DIPSI-2 mixing sequence [23] with a spin-lock period of 90 
ms. All spectra were recorded using the hypercomplex method [24] 
with 400 ti increments and 2048 complex data points in l^. After zero 
filling the final size of the data matrixes were 1024-2048. Data were 
processed on a Sun Sparc workstation using the FELIX software 
(Biosym Technologies, San Diego, CA). One-dimensional spectra 
were acquired with 512 scans, 16 k complex data points and presatu-
ration. 
3. Results and discussion 
Assignment of all the proton resonances in the free form of 
the PapG308-314 peptide was obtained using ROESY and 
TOCSY spectra (Table 1). Two forms of the peptide were 
observed originating from the cisltrans isomerization of the 
amide bond between Phe313 and Pro314. The major form 
had a trans peptide bond and integration of the cross-peaks 
for Pro314 in the TOCSY spectrum showed a cis-content of 
40%. Cisltrans isomerization in aqueous solution has also 
been observed for the longer PapG296-314 peptide with a 
similar cis content [25]. Apart from medium to weak intra-
residue NOEs strong-intensity sequential CaHi/NH i+i NOE 
connectivities were observed between adjacent residues along 
the whole peptide chain in the 200 ms ROESY spectrum (data 
not shown). No sequential NHi/NHj+i or medium- or long-
range NOEs were observed for the free peptide. Altogether, 
these observations indicate that the backbone dihedral angles 
of the peptide are averaged but predominantly in the [3 (ex-
tended chain) region of (|), \|/ space [26]. The absence of a 
preferred conformation is also indicated by the small devia-
tions of the CaH-proton chemical shifts of PapG308-314 as 
compared to random-coil shifts of short peptides [27]. 
The NOESY spectrum of unbound PapG308-314 contains 
no cross-peaks since the correlation time of the peptide is such 
that TUTC ~ 1 resulting in NOEs close to zero (Fig. 1) [28]. On 
addition of PapD (MW=;25 kDa and thus T>JTC:» 1) in sub-
stoichiometric amounts strong cross-peaks appear in the NO-
ESY spectrum (Fig. 1). The much larger rate at which the 
NOEs develop when the ligand is in its bound state allows 
detection of the bound state NOEs under appropriate kinetic 
conditions. In a fast exchange situation, these NOEs are 
transferred into the free ligand population where they persist 
for a time governed by the relaxation time of the free ligand 
protons. Hence, observation of the interproton NOEs of the 
free ligand reveals the distance relationships of the bound 
ligand. 
TRNOEs may also originate from non-specific binding of a 
ligand to a protein or as a result of an increase in the viscosity 
of the solution upon addition of the protein [12]. As a control 
a 200 ms NOESY spectrum was therefore acquired for a sol-
ution of PapG308-314 and the protein Calbindin D28k, which 
has a similar molecular weight as PapD, using a peptide/pro-
tein ratio of 10:1. The spectrum did not show any cross-peaks 
indicating that the interaction between PapG308-314 and 
PapD is specific (data not shown). 
The nature of the TRNOE experiment requires that the rate 
of exchange of the ligand between the free and bound states 
must be faster than the proton relaxation rate [12]. In the 
present study fast exchange has been obtained by the choice 
of peptide. If the rate of peptide association with PapD is 
diffusion limited (108 M _ 1 s_1) and the dissociation constant 
~ 10~6 M, as measured for a modified PapG307-314 peptide 
(Soto G., personal communication), the off-rate is calculated 
to be about 100 s_1. Since PapG308-314 is a weaker inhibitor 
than the 8-mer PapG307-314, the ofT-rate of PapG308-314 
should be even higher, thus corresponding to the fast ex-
change regime. 
No intermolecular TRNOEs between the ligand and the 
Table 1 
Chemical shifts for PapG308-314 in aqueous phosphate buffer, pH 6.0, at 27°C 
Residue 
Thr308 
Met309 
V a l 3 1 0 
Leu311 
Ser312 
Phe313 
Pro314 
Chemical shifts 
HN 
a 
a 
8.32 
8.33 
8.32 (8.34) 
8.37 (8.38) 
7.99 (8.00)c 
8.18 
8.19 
8.01 
(ppm) 
C aH 
4.09 
4.53 
4.04 (4.05) 
4.07 
4.33 (4.34) 
4.40 
4.36 (4.37)c 
4.43 
4.88 
4.65 
4.24(4.25) 
3.66 
C^H 
3.81 
1.98, 2.04 (2.01)b 
1.97 
2.00 
1.43 (1.44), 1.56 
1.54, 1.61 
3.66b 
3.76b 
2.85, 3.20 (2.86, 3.21) 
2.93b 
1.91, 2.20 
1.80, 1.85 
CTH 
1.26 
2.53b 
0.85, 0.90 
0.90b 
1.56 
1.61 
1.97b 
1.67b 
Other 
2.08 (CEH3) 
0.83, 0.90 (C6H3) 
0.86, 0.92 (C6H3) 
7.28, 7.33 (H-arom) 
7.23, 7.35, 7.31 (H-arom) 
3.66 (3.67), 3.71 (CSH) 
3.30, 3.47 (CSH) 
The chemical shifts for the cis form about the Phe-Pro amide bond are given on the second row. Numbers in parenthesis indicate the chemical 
shifts when PapD is present. 
BNot observed due to fast amide proton exchange. 
bDegeneracy has been assumed. 
cBroad resonances, chemical shift determination uncertain. 
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Fig. 1. A portion of the 200 ms NOESY spectrum of the PapG308-314 peptide alone (A,C) and in the presence of 20 uM PapD (B,D). The 
NH/C aH (A,B) and NH/NH (C,D) regions are shown. Mainly TRNOEs corresponding to sequential CaHi/NH i+i were observed (marked with 
letters of the corresponding amino acid in (B)) indicating that the peptide is bound by PapD in an extended conformation. All spectra are plot-
ted at equal threshold. Pulse field gradients were used for water suppression and therefore exchange peaks to water are visible. 
protein were observed in the spectra since the PapD concen-
tration used in the experiment (0.02 mM) was too low to 
enable such observations. However, the low PapD concentra-
tion had the advantage that no cross-peaks from the protein 
that interfered with the resonances of the peptide were ob-
tained. This simplified the interpretation of the peptide 
TRNOEs. 
Both the cis and trans forms of the PapG308-314 peptide 
were observed to have TRNOEs indicating the ability of 
PapD to bind both forms. In the trans form strong sequential 
CaHi/NH i+1 TRNOEs were observed between Met
309 through 
Phe313 and one C^Hi/NHj+i TRNOE was observed between 
Ser312 and Phe313. Weak intraresidue CaH;/NHi TRNOEs 
were observed for Leu311 and Phe313, and weak intraresidue 
C^Hi/NH; TRNOEs were observed for Val310, Ser312 and 
Phe313. In addition, the characteristic NOEs between Phe313 
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Fig. 2. Selected parts of a one-dimensional spectrum of the PapG308-314 peptide alone (upper) and in the presence of 20 uM PapD (lower). 
Stars indicate resonances that are broadened and shifted in the presence of PapD. Resonances for Leu311 NH and Ser312 NH are marked in 
(A), the Ser312 CaH and Leu311 CaH resonances are marked in (B) and resonances for the two CPH protons of Phe313 are marked in (C). 
CaH and the Pro314 C5H protons were observed. The cis form 
displayed sequential CaH;/NHi+1 TRNOEs between Leu
311 
through Phe313 and intraresidue C^Hi/NH; TRNOEs for 
Ser312 and Phe313. In general, TRNOEs in the cis form were 
much weaker than corresponding TRNOEs in the trans form 
indicating a weaker binding and the cis form was therefore 
discarded from further analysis. 
The absence of sequential NHi/NHi+i TRNOEs in the NO-
ES Y spectra suggests that the PapG308-314 peptide is in an 
extended conformation while bound by PapD. However, the 
absence of NHi/NHi+i cross-peaks could be the result of res-
onance broadening. For PapG308-314 only the amide proton 
resonances of Leu311 and Ser312 displayed broadening in the 
presence of PapD. These effects were too small to extensively 
affect any cross-peak intensity and in particular to completely 
suppress any sequential NHi/NHi+i TRNOEs. In a-helices 
sequential NHi/NHi+i NOEs are of equal or stronger intensity 
as intraresidue CaH;/NHi NOEs in extended conformations 
Met 309 
Pro 314 
Thr 308 
Fig. 3. Part of the crystal structure of the PapD/PapG296-314 complex [8]. The C-terminal seven amino acids of PapG296-314 that interact 
with Arg8 and with residues Ala106-Lys112 in the Gl p-strand of PapD are shown with intermolecular hydrogen bonds indicated with arrows. 
Resonances of hydrogen atoms which are broadened in the presence of PapD are marked with a cross. Only NH, CaH and CPH hydrogen 
atoms are displayed. Oxygen atoms are black, whereas nitrogen and sulfur atoms are dark and light gray, respectively. 
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[29]. Despite the low pep tide concentration used here weak 
intraresidue CaHj/NHj cross-peaks were observed for Leu311 
and Phe313 in the NOESY spectra (the CaHi/NHi cross-peak 
for Val310 was not observed due to overlap and the one for 
Ser312 was absent) indicating that the absence of NH ;/NH i+1 
cross-peaks is not due to insufficient S/N ratio. In addition, 
further support for the extended conformation of the peptide 
when bound by PapD is provided by the small size of the 
intraresidue CaHi/NHi TRNOEs relative to the sequential 
CaHi/NH i+i TRNOEs [26]. Altogether, this pattern with 
strong sequential CaHi/NHi+i TRNOEs compared to weak 
or absent intraresidue CHi/NH; TRNOEs and the absence 
of sequential NHi/NH i+1 TRNOEs indicates an extended con-
formation of the PapG308-314 peptide when bound by PapD. 
A conformation which is in agreement with the recently de-
termined crystal structure of PapG296-314 complexed with 
PapD [8]. Additional TRNOEs observed in the spectra orig-
inate from intraresidue C aH and side chain protons except for 
two medium range TRNOEs. The side chain methyl protons 
of Val310 and Leu311 show proximity to the C^H protons of 
Ser312 and the aromatic ring protons of Phe313, respectively. 
This is also in agreement with an extended, p-strand structure 
for PapG308-314 in which the side chains of Val310 and Ser312 
are on one side of the P-strand and those of Leu311 and Phe313 
on the other. 
Spin diffusion in large proteins, leading to intense cross-
peaks even for protons which are not close in space, is a 
well known problem. The observed TRNOEs for PapG308-
314 could therefore be affected by spin diffusion through pro-
tons of the protein. This type of indirect transfer of magnet-
ization can be alleviated by keeping the fraction of bound 
peptide low [30] and a 25:1 ratio between PapG308-314 and 
PapD was therefore used here. Indirect transfer of magnet-
ization appears with opposite sign from cross-peaks originat-
ing from direct transfer in the rotating frame and thus inter-
fere destructively [12]. In the ROESY spectrum of PapD 
bound PapG308-314 no such effects could be observed for 
the sequential TRNOEs but the two medium range TRNOEs 
between the side chains of Val310 and Ser312 and between 
Leu311 and Phe313 were absent in the ROESY spectrum 
(data not shown). Therefore the observed medium range 
TRNOEs most likely arise from direct transfer in combination 
with some spin diffusion effects. Taking this into account, the 
intensities of the medium range TRNOEs corresponds well 
with the measured distances in the PapD-peptide crystal struc-
ture where the distances between the side chains of Val310 and 
Ser312 and between Leu311 and Phe313 are 4.5^1.9 A and 3.8-
7.2 A, respectively. In addition, the occurrence of spin diffu-
sion indicate closeness to a protein proton. In the crystal 
structure the side chain protons of Thr109 and He111 could 
act as such mediators for the NOE between Leu311 and 
Phe313 and the side chain of Lys110 could act as a mediator 
for the NOE between Val310 and Ser312. 
Further information on the mode of interaction of 
PapG308-314 with PapD was obtained from differential line-
broadening and chemical shifts. Selected regions from one-
dimensional spectra of the peptide-protein and free peptide 
solutions are displayed in Fig. 2. The C aH resonances of 
Leu311 and Ser312 are considerably more broadened in the 
presence of PapD. Furthermore, the C^IT resonances of 
Phe313show a significant broadening as do the C^H protons 
of Leu311 and Met309. Small effects could also be seen on the 
119 
amide proton resonances of Ser312 and Leu311. The C aH res-
onances of Met309 and Phe313 could not be observed due to 
their closeness to the water resonance. The amide proton res-
onances of Thr308 and Met309 were absent in the spectra due 
to fast amide proton exchange. In addition, the cross-peaks 
involving Ser312 NH/CPH, Ser312 CaH/CPH and Leu311 NH/ 
C aH were significantly broadened in a TOCSY spectrum of 
PapG308-314 in the presence of PapD (data not shown). The 
cross-peak between Ser312 NH and C a H was absent, probably 
broadened beyond detection. Broadening of resonances is a 
consequence of large chemical shift differences between the 
free and bound form of the peptide. All of the above protons 
affected by broadening also showed chemical shift changes 
upon addition of PapD (Table 1). The broadening effects 
clearly indicate that the backbone of residues Leu311 and 
Ser312, and the side chains of Met309, Leu311 and Phe313 are 
mostly affected by contacts to the Gl strand of PapD. This is 
in perfect agreement with the orientation of the PapG296-314 
peptide in the crystal structure [8] (Fig. 3). 
Finally, the aggregation state of PapD in the presence and 
absence of peptides (PapG296-314 and PapG308-314) was in-
vestigated using asymmetrical flow field-flow fractionation 
[13]. Using this technique no dimers or higher aggregates 
could be detected for PapD in solution, confirming the dimer 
observed in the crystal is an artefact caused by crystal pack-
ing. 
Based on TRNOE studies and differential line-broadening 
we have found that the peptide PapG308-314 binds to the 
chaperone PapD in an extended, P-strand like conformation 
in aqueous solution. Furthermore, the side chains of Met309, 
Leu311 and Phe312 in the peptide make important contacts 
with PapD. Importantly, this is the conformation and the 
contacts found recently in the crystalline complex of PapD 
and the longer peptide PapG296-314. The crystalline complex 
contains PapD-peptide dimers, which could not be detected 
for complex formation in solution. We therefore conclude that 
dimerization has not substantially affected the conformation 
of the peptide and its interactions with PapD found in the 
crystal. 
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